CA2449213A1 - Ophthalmic compositions comprising hyaluronic acid - Google Patents

Ophthalmic compositions comprising hyaluronic acid Download PDF

Info

Publication number
CA2449213A1
CA2449213A1 CA002449213A CA2449213A CA2449213A1 CA 2449213 A1 CA2449213 A1 CA 2449213A1 CA 002449213 A CA002449213 A CA 002449213A CA 2449213 A CA2449213 A CA 2449213A CA 2449213 A1 CA2449213 A1 CA 2449213A1
Authority
CA
Canada
Prior art keywords
composition according
ophthalmic
treatment
composition
ketotifen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002449213A
Other languages
English (en)
French (fr)
Inventor
Jean-Claude Bizec
Andrea Fetz
Maggy Babiole Saunier
Christian Schoch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2449213A1 publication Critical patent/CA2449213A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CA002449213A 2001-06-08 2002-06-07 Ophthalmic compositions comprising hyaluronic acid Abandoned CA2449213A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP01113959 2001-06-08
EP01113958.1 2001-06-08
EP01113959.9 2001-06-08
EP01113958 2001-06-08
EP01115097.6 2001-06-21
EP01115096.8 2001-06-21
EP01115096 2001-06-21
EP01115097 2001-06-21
PCT/EP2002/006279 WO2002100437A2 (en) 2001-06-08 2002-06-07 Ophthalmic compositions comprising hyaluronic acid

Publications (1)

Publication Number Publication Date
CA2449213A1 true CA2449213A1 (en) 2002-12-19

Family

ID=27440131

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002449213A Abandoned CA2449213A1 (en) 2001-06-08 2002-06-07 Ophthalmic compositions comprising hyaluronic acid

Country Status (9)

Country Link
EP (1) EP1404370A2 (es)
JP (1) JP2005508866A (es)
CN (1) CN1514735A (es)
AR (1) AR034371A1 (es)
AU (1) AU2002314149A1 (es)
BR (1) BR0210139A (es)
CA (1) CA2449213A1 (es)
PE (1) PE20030206A1 (es)
WO (1) WO2002100437A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002345015A1 (en) * 2001-06-08 2002-12-23 Novartis Pharma Gmbh Ophthalmic once-a-day composition
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
JP2004143155A (ja) * 2002-10-01 2004-05-20 Taisho Pharmaceut Co Ltd 眼科用剤
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
ES2431640T3 (es) * 2003-08-21 2013-11-27 Sucampo Ag Composición oftálmica que comprende éster isopropílico de unoprostona y un agente de viscosidad
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
JP2007518804A (ja) * 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
DE102005035986B4 (de) * 2005-07-28 2009-10-15 Bausch & Lomb Incorporated Steriles tropfbares mehrphasiges emulgatorfreies ophthalmisches Präparat
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
CN100408046C (zh) * 2005-12-22 2008-08-06 涂家生 大环内酯类抗生素玻璃酸钠眼用传输系统
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
CA2813734A1 (en) * 2010-10-04 2012-04-12 Activbiotics Pharma, Llc Use of rifalazil and analogues thereof to treat ocular disorders
KR101412776B1 (ko) * 2013-03-11 2014-07-01 가톨릭대학교 산학협력단 각결막염 치료용 점안제 조성물 및 이의 제조 방법
US9833441B2 (en) 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10617763B2 (en) 2013-08-28 2020-04-14 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US11179327B2 (en) 2013-08-28 2021-11-23 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US9844537B2 (en) 2013-08-28 2017-12-19 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10307408B2 (en) 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
BR112019002967A2 (pt) 2016-08-19 2019-05-14 Orasis Pharmaceuticals Ltd. composição farmacêutica oftálmica, métodos de corrigir presbiopia, de reduzir o tamanho de uma pupila, de induzir miose, de aumentar a profundidade de campo, de diminuir a grandeza de aberrações de ordem superior e de melhorar a acuidade visual não corrigida de perto e de longe, implante, e, kit.
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
RU2089191C1 (ru) * 1994-01-28 1997-09-10 Научно-производственная фирма "Нарт" Способ пролонгирования физиологического эффекта тимолола снижать внутриглазное давление
CA2193149C (en) * 1995-12-22 2002-04-23 David H. Donabedian Cationic therapuetic agents and delivery systems
JPH1160505A (ja) * 1997-05-20 1999-03-02 Senju Pharmaceut Co Ltd 防腐組成物
DE19923829A1 (de) * 1999-05-17 2000-11-23 Ulrich Kluegel Hyaluronat-Wirkstoff-Wasser-Komplex, dessen Herstellung und Verwendung
US6777429B1 (en) * 1999-07-23 2004-08-17 Novartis Ag Ophthalmic composition

Also Published As

Publication number Publication date
JP2005508866A (ja) 2005-04-07
AU2002314149A1 (en) 2002-12-23
AR034371A1 (es) 2004-02-18
WO2002100437A2 (en) 2002-12-19
EP1404370A2 (en) 2004-04-07
CN1514735A (zh) 2004-07-21
WO2002100437A3 (en) 2003-04-24
PE20030206A1 (es) 2003-04-09
BR0210139A (pt) 2004-06-08

Similar Documents

Publication Publication Date Title
CA2449213A1 (en) Ophthalmic compositions comprising hyaluronic acid
CA2457034C (en) Ophthalmic composition comprising an ascomycin
JP5549669B2 (ja) 眼科用組成物、ドライアイ治療剤及びビタミンａの安定化方法
JP5736635B2 (ja) ドライアイ治療剤
RU2330668C2 (ru) Применение римексолона для лечения синдрома сухого глаза
US6107343A (en) Ophthalmic and aural compositions containing diclofenac potassium
JP7324566B2 (ja) 水性眼科組成物
WO2020018498A1 (en) Cyclodextrin formulations
AU2002331172A1 (en) Ophthalmic composition comprising an ascomycin
EP0938896A1 (en) Autoclavable pharmaceutical compositions containing a chelating agent
JP4699573B2 (ja) シクロデキストリンおよび第四級アンモニウム化合物を含む眼用組成物
RU2630581C2 (ru) Защитное средство для роговицы и конъюнктивы или супрессивное средство при кератоконъюнктивальном нарушении
BRPI0717093A2 (pt) Composições farmacêuticas aquosas autopreservadas
US20240139166A1 (en) Ophthalmic compositions for presbyopia
EP2547340A2 (en) Ophthalmic formulations of cetirizine and methods of use
US20030031718A1 (en) Ophthalmic compositions and use
WO2002100436A2 (en) Ophthalmic once-a-day composition
JP5499535B2 (ja) 眼科用組成物及びなみだ目改善剤
JPH11147825A (ja) 粘膜吸収性の向上方法及び粘膜外用剤
JP2531558B2 (ja) ドライアイ症処置用の性ステロイド膏薬、同薬の調製法および適用法
WO2003011305A1 (en) Composition of glycosaminoglycan and a peroxide for the treatment of dry eye
AU2015252082B2 (en) Povidone iodine, a novel alternative preservative for ophthalmic compositions

Legal Events

Date Code Title Description
FZDE Dead